| Abiraterone in metastatic prostate cancer without previous chemotherapy CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ... New England Journal of Medicine 368 (2), 138-148, 2013 | 3248 | 2013 |
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma RJ Motzer, TE Hutson, D Cella, J Reeves, R Hawkins, J Guo, P Nathan, ... New England Journal of Medicine 369 (8), 722-731, 2013 | 2126 | 2013 |
| Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall … CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ... The Lancet Oncology 16 (2), 152-160, 2015 | 1587 | 2015 |
| Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial JAMA Oncology 6 (7), 1003-1010, 2020 | 1087 | 2020 |
| Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized … LS Rosen, D Gordon, NS Tchekmedyian, R Yanagihara, V Hirsh, ... Cancer 100 (12), 2613-2621, 2004 | 939 | 2004 |
| Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the … LS Rosen, D Gordon, S Tchekmedyian, R Yanagihara, V Hirsh, ... Journal of Clinical Oncology 21 (16), 3150-3157, 2003 | 914 | 2003 |
| Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma TE Hutson, ID Davis, JPH Machiels, PL De Souza, S Rottey, B Hong, ... Journal of Clinical Oncology 28 (3), 475-480, 2010 | 355 | 2010 |
| Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302) DE Rathkopf, MR Smith, JS De Bono, CJ Logothetis, ND Shore, ... European urology 66 (5), 815-825, 2014 | 353 | 2014 |
| Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies JP Dutcher, P de Souza, D McDermott, RA Figlin, A Berkenblit, A Thiele, ... Medical oncology 26, 202-209, 2009 | 334 | 2009 |
| Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized … TK Choueiri, DJ Figueroa, AP Fay, S Signoretti, Y Liu, R Gagnon, K Deen, ... Clinical Cancer Research 21 (5), 1071-1077, 2015 | 279 | 2015 |
| The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo‐controlled … TH Diamond, J Winters, A Smith, P De Souza, JH Kersley, WJ Lynch, ... Cancer 92 (6), 1444-1450, 2001 | 215 | 2001 |
| Markers of systemic inflammation predict survival in patients with advanced renal cell cancer P Fox, M Hudson, C Brown, S Lord, V Gebski, P De Souza, CK Lee British journal of cancer 109 (1), 147-153, 2013 | 189 | 2013 |
| Emerging roles for phospholipase A2 enzymes in cancer KF Scott, M Sajinovic, J Hein, S Nixdorf, P Galettis, W Liauw, P de Souza, ... Biochimie 92 (6), 601-610, 2010 | 188 | 2010 |
| Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes CF Xu, NX Bing, HA Ball, D Rajagopalan, CN Sternberg, TE Hutson, ... Journal of clinical oncology 29 (18), 2557-2564, 2011 | 186 | 2011 |
| Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study D Goldstein, BK Bennett, K Webber, F Boyle, PL De Souza, NRC Wilcken, ... Journal of clinical oncology 30 (15), 1805-1812, 2012 | 166 | 2012 |
| Dual-drug delivery of curcumin and platinum drugs in polymeric micelles enhances the synergistic effects: a double act for the treatment of multidrug-resistant cancer W Scarano, P De Souza, MH Stenzel Biomaterials science 3 (1), 163-174, 2015 | 164 | 2015 |
| Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results MJ Morris, A Molina, EJ Small, JS De Bono, CJ Logothetis, K Fizazi, ... Journal of Clinical Oncology 33 (12), 1356-1363, 2015 | 155 | 2015 |
| Thiol–yne and thiol–ene “click” chemistry as a tool for a variety of platinum drug delivery carriers, from statistical copolymers to crosslinked micelles VT Huynh, G Chen, P Souza, MH Stenzel Biomacromolecules 12 (5), 1738-1751, 2011 | 141 | 2011 |
| Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer AC Won, H Gurney, G Marx, P De Souza, MI Patel BJU Int 112 (4), E250-E255, 2013 | 136 | 2013 |
| Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant … CJ Ryan, MR Smith, JS De Bono, A Molina, C Logothetis, PL De Souza, ... Journal of Clinical Oncology 30 (18_suppl), LBA4518-LBA4518, 2012 | 136 | 2012 |
